Earlier AXL-IHC studies in NSCLC use different scoring methods and different anti-AXL antibodies, most of which are polyclonal and thus can exhibit nonspecific binding and lot-to-lot variability. The gene discussed is AXL; the disease is non-small cell lung carcinoma.